NF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor

The clinical efficacy of EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations is limited by the emergence of acquired resistance, mostly ascribed to the secondary EGFR-T790M mutation. Selective EGFR-T790M inhibitors have been proposed as a...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncotarget
Autori principali: Galvani, Elena, Sun, Jing, Leon, Leticia G., Sciarrillo, Rocco, Narayan, Ravi S., Tjin Tham Sjin, Robert, Lee, Kwangho, Ohashi, Kadoaki, Heideman, Daniëlle A.M., Alfieri, Roberta R., Heynen, Guus J., Bernards, René, Smit, Egbert F., Pao, William, Peters, Godefridus J., Giovannetti, Elisa
Natura: Artigo
Lingua:Inglês
Pubblicazione: Impact Journals LLC 2015
Soggetti:
Research Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4767465/
https://ncbi.nlm.nih.gov/pubmed/26015408
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi